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Background: Fully covered Self-Expanding metal stents (FCSEMS) have been shown efficacious in palliating
malignant biliary obstructions. There is little data analyzing mucosal response to their temporary placement in the
bile duct.
Methods: Ten mini pigs underwent endoscopic placement of a FCSEMS (Wallflex, Boston Scientific). FCSEMS were
kept in place for three months. At the end of the 3 months, FCSEMS were removed endoscopically. Five pigs were
euthanized and their bile ducts harvested. The other five were kept alive for another month post removal. A single
pathologist, created a scoring system (to determine degree of inflammation, fibrosis, and epithelial injury),
examined all specimens in a blinded fashion.
Results: Four FCSEMS spontaneously migrated in the duodenum. On post mortem examination, mild mucosal
thickness was noted in three bile duct specimens while superficial inflammation of the bile duct was noted in five
animals. Histologic examination of the bile duct revealed focal acute inflammation in both groups. For the 5
animals euthanized immediately after stent removal, there was a tendency to have superficial mucosal erosion and
fibrosis. In contrast, increased chronic inflammation was more commonly seen in the animals 1 month post stent
removal, with all animals in this group showing moderate degrees of mononuclear inflammatory cell mucosal
infiltrates. No severe inflammatory or fibrotic duct injury was observed in any of the study animals, with degree of
injury graded as mild to moderate.
Conclusion: FCSEMS appear to induce minimal tissue overgrowth or fibrosis post placement. Ease of removability
and no significant histologic injury are advantages noted with FCSEMS., however, further studies are needed to
evaluate treating benign biliary strictures with FCSEMS in humans.
Background
In the past decade, self-expanding metal stents (SEMS)
have been preferred for palliation of malignant obstructive
jaundice compared to plastic stents, especially in patients
with longer predicted survival [1-5]. They provide pro-
longed patency, reduced endoscopic sessions, and better
drainage due to their larger diameter [6,7]. A major limita-
tion of uncovered SEMS is their occlusion due to tumor
growth through the uncovered mesh [8,9]. Partially cov-
ered and later fully covered metal stents were created to
prevent this occurrence [8]. In terms of patency, recent
studies do not demonstrate an advantage for covered
metal stents, however, the ability to remove them offer the
option of treating benign biliary strictures [10-12].
Partially covered metal stents when studied for benign
biliary strictures were associated with migration and
epithelial hypertrophy at the level of the uncovered por-
tion of the metal stent [13,14]. Fully covered metal stent
with fins had their own set of complications probably
related to their high radial force and anti-migratory fins
[15-17].
A recently developed FCSEMS with flared ends, with-
out fins might offer a higher resolution rate, if placed
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any medium, provided the original work is properly cited.temporarily in the bile duct, with limited complications
[18]. Currently, there is limited data analyzing mucosal
response to their temporary placement in the bile duct.
With the evolution of stents, the pathologic changes
that can occur in the bile duct are still not clear. Indeed
few animal studies have been done to examine various
stents and their effects on the bile duct.
The aim of this study is to establish the safety and his-
tologic effects of temporary FCSEMS placement in a
porcine model.
Methods
The Food and Drug Administration (FDA) and the Uni-
versity of Virginia’s Animal Care and Use Committee
(ACUC #3756) approved the study. A total of 10 female
mini pigs (with acceptable health status and body
weight) were acclimated in the vivarium for at least 3
days after arrival.
Pre-Procedure
The animals were fasted the night before and water
withheld the morning before procedures. Animals were
pre-medicated intramuscularly with atropine sulphate
(0.04 mg/kg) and anesthesia was induced with intramus-
cular Telazol/Xylazine 4-6/2 mg/kg. Propofol 2-3 mg/kg
body weight was administered intravenously to effect to
facilitate intubation. Isoflurane titrated to effect was
administered to maintain anesthesia. Ventilation was
provided via an endotracheal tube.
The animals were placed in recumbence on their left
side on a fluoroscopy table. Vitals sign were continu-
ously monitored during the procedure as well as distress
or pain.
Endoscopic Procedure
A Fuji duodenoscope (ED-250XT5, Fujinon) was used
for all endoscopic procedures. Endoscopic Retrograde
Cholangiography using standard technique was per-
formed using a triple lumen sphincterotome from Bos-
ton Scientific (Ultratome, Natick, MA) by a single
endoscopist performing more than 500 ERCPs annually
(MK). The bile duct anatomy was delineated under
fluoroscopy (Figure 1A), and wire advanced into the bili-
ary tree. The FCSEMS (Diameter of 8 or 10 mm) (Wall-
flex, Boston Scientific) was deployed under fluoroscopy
and endoscopic visualization to confirm good decom-
pression (Figure 1B).
Post-Procedure Follow-up
After the procedure, the animals were monitored con-
tinuously until fully recovered from anesthesia. Yohim-
bine (0.3 mg/kg) was administered during recovery from
anesthesia and ketoprofen (0.5-1.0 mg/kg q 12 hr) with
perceived level of need for post-operative analgesia. The
animals were monitored daily by a veterinary technician.
Clinical signs including weight loss, pain, or jaundice
were monitored as well as daily food intake, respiratory
rate, heart rate, and demeanor score (scored as follows:
1 = normal; 2 = slightly to moderately depressed, listless,
will stand; 3 = severely depressed, recumbent, will not
stand) for the first month following FCEMS placement
and weekly thereafter. Subsequently all animals had
blood drawn (7 cc) at 2 weeks, 1.5 months, 2.5 months
and as needed if the animal showed any clinical signs of
malaise. Blood tests included: Total bilirubin (TB), Alka-
line Phosphatase (ALK) and Cell blood Count (CBC).
The primary investigator (MK) reviewed any abnormal
laboratory values.
Necropsy
At three months, all animals underwent endoscopic
FCSEMS removal. The procedure for removal was simi-
lar to placement as described above including evaluating
FCSEMS position and any tissue reaction or food
impaction. The stent was grasped with a snare or for-
ceps under endoscopic control (Figure 1C). Contrast
injection via catheter was used to assess ductal anatomy
post removal under fluoroscopy (Figure 1D).
Five of the 10 animals were euthanized (Euthanasia
Solution 5 gr/ml 1 cc/10 lbs) and their bile duct har-
vested for histologic examination. The bile duct was
removed from the hepatic bifurcation to the duodenum,
including a portion of duodenum and the ampulla. The
duct was then opened longitudinally and examined for
Figure 1 Ercp Images for Stent Placment and Removal. 1A:
Endoscopic Retrograde Cholangiography prior to Fcsems Placement
1B: Fluoroscopy Showing Complete Biliary Decompression after
Fcsems Placement 1C: Rat Tooth Removal of the Fcsems 1D:
Endoscopic Retrograde Cholangiography after Fcsems Removal
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then preserved in formalin and sent histological analysis.
The remaining 5 animals were observed for one
month. After one month, they underwent repeat ERC
before being euthanized and their bile duct harvested
for histologic examination.
Histopathology
The histologic specimens examined were longitudinal
sections taken from each bile duct that included the
ampulla (Figure 3). The sections were examined with a
hematoxylin & eosin (H&E) stain for general histologic
features (Figures 3A and 3B). Collagen deposition, as
evidenced by increased blue staining on a Masson tri-
chrome stain (Figures 3C and 3D), was interpreted as
fibrotic injury.
The dedicated scoring system described in Table 1
was applied by a single pathologist in a blinded fashion
to quantify inflammation, fibrosis, and epithelial injury.
Results
Initial Placement
All 10 pigs had successful placement of a fully covered
WallFlex stent, three pigs received a 10 mm × 40 mm
stent and seven received an 8 mm × 60 mm stent. The
stents were deployed proximal to the papilla and con-
firmed in proper position under fluoroscopy. Three of
the pigs (Pig #1, 7, 10) had complications during the
initial procedure. One pig had a wire perforation on a
peripheral branch of the biliary tree noted under con-
trast injection during stent placement. Two other pigs
had a contained perforation of the bulb during a chal-
lenging biliary cannulation, requiring the procedure to
be postponed for 6 and 8 days, while the animal were
treated with omeprazole (20 mg/d) to reduce inflamma-
tion. All three pigs were managed conservatively and
fully recovered post procedure.
Clinical Follow-up
For the next three months, monitoring of the pigs
included clinical parameters:, i.e.: respiratory rate, heart
rate, and demeanor score daily as well as daily food
intake for the first month and then weekly. The median
change in weight was 16.8 kg with all mini-pigs gaining
weight.
Total bilirubin was within normal range for the 2
week, 1.5 month, and 2.5 month interval. All ten pigs
had low alkaline phosphatase through each interval with
no significant rise. Only one pig had a clinically insignif-
icant decrease in hemoglobin in the first two week inter-
val and then normal at 1.5 and 2.5 months. Eight pigs
had low WBC at the two week interval however there
was no significant increase in WBC. Pig #1, 2, 4, and 5
were noted to have uneventful stent migration between
41 to 57 days after deployment, all found in the feces of
the animal.
Repeat procedure
At the three-month interval, repeat ERC was performed
for stent removal in 6 pigs (4 pigs had stent migration
as described above). Five pigs (#3, 6, 7, 8, 9) had stent
removal with a rat tooth forceps or snare without diffi-
culty. Pig #10 couldn’t have his stent (10 × 40 mm)
removed using the rat tooth forceps technique as the
stent had migrated proximally into the bile duct.
Figure 2 Macroscopic examination of the bile duct showing
superficial inflammation.
Figure 3 Normal histology of porcine common bile duct. 3A:
Intact biliary mucosa overlying a thin fibromuscular wall. Adipose
tissue comprises the majority of the adventitia. (original
magnification 40×, H&E stain) 3B: Only scattered mononuclear cells
are present in the biliary mucosa. (original magnification 400×, H&E
stain) 3C: Masson trichrome stain highlights normal collagen
content (blue staining) (original magnification 40×) 3D: Normal
collagen fibers are thin and reticular in nature. (original
magnification 400×, Masson trichrome stain).
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mm CRE balloon (Boston scientific) allowing the stent
to be pulled out from the bile duct. Histological exami-
n a t i o nr e v e a l e d5( # 2 ,3 ,5 ,6 ,8 )o ft h e1 0a n i m a l sh a d
focal mild acute inflammation. Focal acute inflammation
was seen in both groups of animals (Figure 4A).
For the animals euthanized immediately after stent
removal, there was a tendency to have more acute
epithelial injury (Figure 4B) in the form of superficial
mucosal erosion (4/5 vs 2/5) and mild to moderate
mucosal fibrosis (3/5 vs 0/5) (Figure 4C).
In contrast, increased chronic inflammation (Figure
4D) was more commonly seen in the animals 1 month
post stent removal (5/5 vs 2/5), with all animals in this
group showing moderate degrees of mononuclear
inflammatory cell mucosal infiltrates.
The degree of injury was mild to moderate both in
acute and chronic inflammation, with no animal showing
severe injury. Specifically, there was no abscess formation,
deep tissue involvement by chronic inflammation, severe
fibrosis, or mucosal ulceration (Table 2).
Discussion
Fully covered self-expanding metal stents without fins
offer adequate biliary drainage in malignant obstruction
and potential advantages including reduction in mucosal
hyperplasia and migration [12]. These benefits present
an attractive option for benign biliary strictures, which
c a nb ec l i n i c a l l yc h a l l e n g i ng to treat with serious and
often irreversible complications [19,20].
This study analyzes the histologic changes in the bile
duct induced by temporary placement of FCSEMS. This
particular FCSEMS has a platinol wiring, associated with
increased flexibility and radiopacity compared to its pre-
decessor, the partially covered Wallstent [21]. The close
cell construction and double coating should reduce tis-
s u ei n g r o w t hw h i l et h el o o p e da n df l a r e de n d sa r e
intended to reduce tissue trauma and stent migration.
Previous studies have examined the effects of stent
placement on the bile duct, but were not designed to
provide a histologic grading system for the changes
noted. Silvis et al examined surgically placed covered
and uncovered wire mesh stents (Wallstent 5 mmx23
mm) in the canine biliary tract and showed mild to
moderate cellular infiltration in all animals and marked
mucosal hyperplasia with uncovered stents [22]. Van Os
et al examined self expanding spiral nitinol stents in a
porcine model but had technical limitations in stent pla-
cement and removal, related to disparity in stent and
duct size or faulty release mechanism (3 of 6 animals).
They showed moderate inflammation and fibrosis in 4
of 6 animals euthanized 3 months after stent deploy-
ment and mild inflammation in 2 animals kept alive one
more month [23]. Further, Ginsberg et al studied bioab-
sorbable biliary stents in a porcine model, which
remained patent up to 6 months with no bile duct inte-
gration or proliferative changes, however, stent occlu-
sion and migration was still encountered [24]. More
recently, Petersen and colleagues examined the ability to
remove partially covered Wallflex stents (within five
minutes of deployment) utilizing a porcine model. They
demonstrated no significant tissue damage leading to
complications [25].
Our objective was to assess the potential changes in
the bile duct epithelium after stent placement. Ten
mini-pigs were selected and clinically monitored after
stent placement for 3 months. Stents were removed or
had migrated from all animals at the end of 3 months.
Clinically, there was no evidence of any biliary
obstruction in the next three months as evidenced by
lack of rising laboratory parameters (bilirubin, alkaline
phosphatase, hematocrit, white blood cell count) or clin-
ical findings (jaundice, decreased food intake, pain,
change in vital signs or demeanor score). Overall, all
Figure 4 Examples of acute and chronic injury. Figure 4A:
Example of acute inflammatory changes. In the center if the
field, polymorphonuclear leukocytes can be seen in the lamina
propria and within the lumen of an injured gland. (original
magnification 400×, H&E stain) Figure 4B: Example of epithelial
injury. Typical example of epithelial erosion in where the superficial
epithelial layer has been denuded. The deeper glandular mucosa
persists and there is no granulation tissue reaction. (original
magnification 200×, H&E stain) Figure 4C: Example of chronic
inflammation. There is an increased population of predominantly
mononuclear inflammatory cells, filling the lamina propria of the
mucosa (original magnification 40×, inset 400×, H&E stain) Figure
4D: Example of fibrosis. Pig #339 showed focal fibrosis that
widened the fibromuscular bile duct wall. The main image shows
the expansion of the wall by collagen (blue staining). The inset
shows thickening and homogenization of the collagen fiber pattern.
(original magnification 100×, inset 400×, H&E stain)
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baseline to stent removal.
During the three-month follow up, four of the animals
were found with the stent in their feces within two
months of placement, without any clinical consequences.
The other six had stent removal with no difficulty,
except one.
Endoscopic findings at 3 months demonstrated a nor-
mal cholangiogram on all animals. Specifically, no biliary
injury was noticed on fluoroscopic examination. Gross
pathologic examination revealed only mild superficial
inflammation in two mini-pigs and mild mucosal thick-
ness in three. The pigs that were euthanized at the 3
month mark included those with stent migration. (Table
1) In addition, of the five mini-pigs kept alive for
another month, three had superficial inflammation
noted after harvesting the bile duct (Table 2).
The histologic examination confirmed mild acute
inflammation in five of the animals, and superficial
mucosal erosion (4/5) and mucosal fibrosis (3/5) in the
animals sacrificed immediately after stent removal. In
contrast, increased chronic inflammation (involving of
mucosal and/or submucosal area) was more commonly
seen in the animals kept alive after stent removal (5/5).
The degree of injury was mild to moderate and no ani-
mal had severe injury classified as abscess formation,
deep tissue inflammatory involvement, severe fibrosis, or
mucosal ulceration.
This study emphasizes the need for a systematic histo-
logic assessment in order to truly understand the impli-
cation associated with temporary metal stent placement.
Using a scoring system developed by our pathologist,
the bile duct histopathologic alterations after temporary
stent placement can be measured and reproduced. This
scoring system once validated has the potential to be
used for biopsy of the bile duct after stent removal in a
patient. Further clinical studies in human subjects using
this scoring system could effec t i v e l yp r o v et h eu l t i m a t e
safety of FCEMS in humans and possibly expand the
indication of metal stents to benign biliary strictures.
Limitations to this study include small sample size.
Early migration of the stents (noted in 4 pigs #1, 2, 4, 5)
was another limitation of this study. All four were ana-
lyzed histologically at 3 months. Even though the migra-
tion occurred from 41-57 days, respectively, they had
similar histologic scores along with the six other pigs.
However, because of the early migration, they should be
considered as having stent deployed for approximately
1.5-2 months. Importantly, we did not evaluate for post-
stenting pancreatitis because of the anatomical differ-
ence that would make it less likely for post-ercp pan-
creatitis in a porcine model. Post-ercp pancreatitis after
FCSEMS placement would be a complication to evaluate
in human studies, especially in benign biliary strictures.
Conclusion
Overall, FCSEMS only appear to induce minimal acute
inflammation and more importantly minimal fibrosis
after stent removal. Chronic inflammation of mild to
moderate degree was noted in the animals alive one
month longer. The inflammation overall appears to have
no clinical effect. Their high rate of migration in the
normal bile duct of the pig suggests the necessity to
induce a stricture before placement. However, it remains
to be determined if FCSEMS can achieve sustained reso-
lution of benign biliary stricture in humans.
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